| CONTACT: Richard R. Current,
Chief Financial Officer,
517/372-9200 |
Neogen reports 35% increase
in net income
LANSING, Mich., Sept. 29, 2005 –
Neogen Corporation (Nasdaq: NEOG) announced today that its net income
for the first quarter of FY 2006, which ended Aug. 31, increased
35% from the previous year’s first quarter. Neogen’s
first quarter revenues were $16,778,000 — a 10% increase compared
to the prior year.
First quarter net income per share
was $0.25 as compared with $0.19 for the same period last year.
The first quarter marked the first time Neogen reported over $2
million of net income in a single three-month period, as net income
rose to $2,140,000 from the prior year’s $1,584,000. The quarter
marked the 50th consecutive profitable quarter from operations for
the company, and was the 54th of the past 59 quarters when Neogen
reported revenue increases as compared with the previous year.
“The first quarter was a great
start for our new fiscal year that will allow us to pursue a wide
array of opportunities,” said James Herbert, Neogen’s
president. “We are able to report that we both grew our top
line at a double-digit pace, and grew our profitability at a pace
that far exceeded our revenue increase. Our first quarter results
are especially significant as the revenue increase reflects a true
same-store year-over-year comparison, and it was the second consecutive
quarter that our net income increased by 35%.”
The first quarter also saw Neogen
continue its progress toward controlling costs to improve operating
results. Neogen’s gross margin as a percentage of sales moved
up impressively to 52.7% of sales, from 50.3% in the closing quarter
of FY 2005, and 49.3% in the prior year’s first quarter. General
and administrative expenses remained within the company’s
target range — under 8% of sales. As a result of its cost-controlling
efforts, Neogen’s operating income increased to 18.5% of sales
compared with 16.0% in the prior year.
“The consolidation of our Chicago
operations 16 months ago, and our Baltimore operations last year,
were completed to help us achieve the kind of improved operating
results that we are now reporting,” said Lon Bohannon, Neogen’s
chief operating officer. “We will continue to diligently look
for ways to improve margins by streamlining operations and improving
operating efficiencies wherever possible.”
Neogen’s Animal Safety Division
led the company’s first quarter revenue increase, with sales
up 13% from $8,012,000 in FY 2005 to $9,088,000 in FY 2006. Sales
of Neogen’s Hacco subsidiary rodenticide products paced the
division’s sales growth with an increase of 38% over the prior
year. In a quarter-to-quarter comparison, Hacco’s sales were
especially strong internationally and in agricultural markets.
Sales of Neogen’s veterinary
instruments continued their strong positive momentum, increasing
11% in the quarter compared to FY 2005. Veterinary instrument revenues
were bolstered by continuing improvement in sales to the nation’s
farmers and ranchers through multiple distribution channels.
Sales of the Animal Safety diagnostics
group also moved ahead strongly, increasing 11% over the prior year.
This group’s sales improved as a result of stronger sales
of test kits to detect drug residues, and Neogen’s proprietary
life science products.
Neogen’s Food Safety Division
first quarter revenues were up 7% to $7,690,000. Sales of the company’s
expanding line of food allergen test kits increased 41% for the
quarter compared to the prior year’s comparable quarter. A
new U.S. food allergen labeling law that goes into effect January
1 should help growth of food allergen test sales in 2006 and beyond.
Neogen has the leading group of diagnostic tests to detect food
allergens such as peanuts, milk, eggs, gluten, almonds, and soy.
Sales of Acumedia dehydrated culture
media products to food producers and processors continued their
strong improvement in the quarter, increasing 14% over the prior
year’s comparable quarter. The opportunity to increase Acumedia
sales led Neogen to a decision in November 2004 to consolidate its
outdated Baltimore dehydrated culture media operations into newly-renovated
space in its Lansing, Mich., facilities. The new facilities and
processing equipment have dramatically improved operating efficiency,
and significantly increased manufacturing capacity and flexibility.
The first quarter also saw the continuation
of the beneficial effects of Neogen’s expansion of its Neogen
Europe Ltd. operations in Scotland. Neogen Europe’s sales,
which represent a combination of sales of Neogen products produced
in the U.S. specifically for the EU market and diagnostics manufactured
in Scotland, increased 18% in FY 2006 over the prior year’s
first three months. Since it purchased the Scottish business in
2003, Neogen has expanded Neogen Europe’s role to become the
center of distribution and focal point for Neogen’s business
development in the EU.
Neogen Corporation develops
and markets products dedicated to food and animal safety. The company’s
Food Safety Division markets dehydrated culture media, and diagnostic
test kits to detect foodborne bacteria, natural toxins, genetic
modifications, food allergens, drug residues, plant diseases and
sanitation concerns. Neogen’s Animal Safety Division markets
a complete line of diagnostics, veterinary instruments, veterinary
pharmaceuticals, nutritional supplements, disinfectants, and rodenticides.
NEOGEN
CORPORATION SUMMARIZED UNAUDITED
CONSOLIDATED OPERATING DATA
|
(In thousands, except for
percentages and per share amounts)
|
|
|
|
|
| Revenue |
Food Safety |
|
|
| |
Animal Safety |
|
|
| Total revenue |
|
|
|
| Cost of sales |
|
|
|
| |
Gross margin |
|
|
| Other expenses |
|
|
|
| |
Sales & marketing |
|
|
| |
Administrative |
|
|
| |
Research & development |
|
|
| Total other expenses |
|
|
|
| Operating income |
|
|
|
| Other revenue |
|
|
|
| Income before tax |
|
|
|
| Income tax |
|
|
|
| Net income |
|
|
|
| Net income per diluted share |
|
|
| |
| Other information: |
|
|
|
| |
Shares to calculate per share |
|
|
| |
Depreciation & amortization |
|
|
| |
Interest expense |
|
|
| |
Gross margin (% of sales) |
|
|
| |
Operating income (% of sales) |
|
|
| |
Revenue increase vs. FY 2005 |
|
|
| |
Net income increase vs. FY 2005 |
|
|
NEOGEN
CORPORATION SUMMARIZED UNAUDITED
CONSOLIDATED BALANCE SHEET DATA
(In thousands)
|
|
|
|
|
|
|
|
|
| Assets |
|
|
|
| Current assets |
|
|
|
| |
Cash & investments |
|
|
| |
Accounts receivable |
|
|
| |
Inventory |
|
|
| |
Other current assets |
|
|
| Total current assets |
|
|
|
| Property & equipment |
|
|
|
| Goodwill & other assets |
|
|
|
| Total assets |
|
|
|
| |
|
|
|
| Liabilities & Stockholders’ Equity |
|
|
|
| Current liabilities |
|
|
|
| |
Accounts payable |
|
|
| |
Other current liabilities |
|
|
| Total current liabilities |
|
|
|
| Long-term lines of credit |
|
|
|
| Other long-term liabilities |
|
|
|
| Stockholders’ equity—shares outstanding 8,220
in ‘06 & 8,147 in ‘05 |
|
|
|
| |
|
|
|
| Total liabilities & stockholders’ equity |
|
|
|
Certain portions of this news release
that do not relate to historical financial information constitute
forward-looking statements. These forward-looking statements are
subject to certain risks and
uncertainties. Actual future results and trends may differ materially
from historical results or those
expected depending on a variety of factors listed in Management’s
Discussion and Analysis of
Financial Condition and Results of Operations in the Company’s
most recently filed Form 10-K.
|